APIXABAN TEVA
2,5MG TBL FLM 180 II
SÚKL code | 0239396 |
---|---|
Name of the product | APIXABAN TEVA |
_MA_MEDICATION_DETAIL_INFO_MED_NAME i | APIXABAN TEVA |
Supplement | 2,5MG TBL FLM 180 II |
Strenght | 2,5MG |
Pharmaceutical form | Film-coated tablet |
Package | 180 II |
Route | Oral use |
Language of the pack | Czech |
Wrap type | Tablet container |
Legal status | na lékařský předpis |
Active substance | APIXABAN (APIXABANUM) |
ATC group | B01AF02 |
ATC group name | APIXABAN |
Marketing authorisation information
Registration Number | 16/ 217/19-C |
---|---|
Type of MA | A mutual recognition procedure (MRP, DCP), where CZ is Concerned member state |
MA status | B - medicinal product after change, may be placed on the market for the period of 6 months (Placed on the market till) and used until expiration, not later than till the end of validity of the marketing authorisation (Valid till) |
Placed on the market till | 30. 11. 2021 |
MA Holder | Teva B.V., Haarlem |
MA Holder country | NIZOZEMSKO |
Actual MA holder | Teva Pharmaceuticals CR, s.r.o., Praha |
Actual MA holder country | ČESKÁ REPUBLIKA |